Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 22 10:26AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.72 Insider Own13.60% Shs Outstand47.82M Perf Week-9.48%
Market Cap341.34M Forward P/E- EPS next Y-2.22 Insider Trans0.00% Shs Float41.71M Perf Month-15.13%
Income-76.87M PEG- EPS next Q-0.55 Inst Own100.94% Short Float17.20% Perf Quarter-47.00%
Sales0.00M P/S- EPS this Y-29.17% Inst Trans-19.25% Short Ratio5.31 Perf Half Y-63.71%
Book/sh4.60 P/B1.54 EPS next Y-3.98% ROA-44.70% Short Interest7.18M Perf Year-48.81%
Cash/sh4.64 P/C1.52 EPS next 5Y- ROE-49.06% 52W Range6.90 - 26.35 Perf YTD-68.85%
Dividend Est.- P/FCF- EPS past 5Y-26.63% ROI-34.55% 52W High-73.17% Beta2.42
Dividend TTM- Quick Ratio12.66 Sales past 5Y0.00% Gross Margin- 52W Low2.46% ATR (14)0.71
Dividend Ex-Date- Current Ratio12.66 EPS Y/Y TTM5.35% Oper. Margin0.00% RSI (14)35.20 Volatility7.56% 8.44%
Employees103 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price33.56
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-13.60% Payout- Rel Volume0.14 Prev Close7.09
Sales Surprise- EPS Surprise-7.28% Sales Q/Q- EarningsMay 15 BMO Avg Volume1.35M Price7.07
SMA20-7.57% SMA50-27.07% SMA200-56.26% Trades Volume34,657 Change-0.28%
Date Action Analyst Rating Change Price Target Change
Feb-05-24Initiated Jefferies Buy $36
Nov-29-23Initiated William Blair Outperform $38
Oct-24-23Initiated Cantor Fitzgerald Overweight $40
Oct-19-23Initiated Stifel Buy $31
Sep-05-23Initiated Citigroup Buy $22
Jul-18-23Initiated Guggenheim Buy $34
Jan-27-23Upgrade Morgan Stanley Equal-Weight → Overweight $3 → $16
Aug-30-22Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $3
Dec-08-21Initiated Wells Fargo Overweight $17
Oct-19-21Resumed Morgan Stanley Overweight $20
Jul-08-24 07:01PM
Jul-02-24 08:00AM
Jun-14-24 02:00AM
May-29-24 08:00AM
05:23PM Loading…
May-16-24 05:23PM
May-15-24 11:54AM
May-13-24 08:00AM
Mar-23-24 05:31AM
Mar-21-24 01:53PM
Mar-20-24 07:00AM
Mar-08-24 08:50AM
Feb-27-24 10:11AM
08:00AM Loading…
Feb-01-24 04:30PM
Jan-31-24 08:00AM
Jan-08-24 07:00AM
Jan-02-24 08:00AM
Dec-18-23 08:49PM
Nov-28-23 04:30PM
Nov-09-23 08:10AM
Nov-06-23 08:15AM
Oct-30-23 08:00AM
Oct-09-23 09:40AM
Oct-02-23 09:14AM
11:00AM Loading…
Oct-01-23 11:00AM
Sep-25-23 08:50AM
Sep-19-23 08:00AM
Sep-01-23 02:00PM
Aug-31-23 09:55AM
Aug-30-23 08:00AM
Aug-25-23 10:13AM
Aug-23-23 08:50AM
Aug-22-23 08:00AM
Aug-15-23 01:46PM
Aug-10-23 07:00AM
Aug-01-23 10:00AM
Jul-24-23 08:00AM
Jul-18-23 02:58PM
Jun-20-23 08:00AM
Jun-08-23 11:14AM
May-31-23 08:00AM
May-24-23 07:33AM
May-22-23 04:30PM
May-17-23 10:16PM
May-16-23 07:00AM
May-11-23 08:39AM
May-02-23 04:35PM
May-01-23 07:00AM
Apr-25-23 01:07PM
Apr-13-23 04:30PM
Mar-31-23 07:00AM
Mar-16-23 07:00AM
Mar-14-23 07:14AM
Feb-28-23 08:00AM
Feb-19-23 10:53AM
Feb-17-23 06:43PM
Feb-06-23 12:00PM
Jan-31-23 09:40AM
Jan-09-23 07:00AM
Jan-05-23 08:00AM
Jan-03-23 05:40AM
Dec-30-22 09:03AM
Dec-23-22 09:40AM
Dec-13-22 11:41AM
Dec-12-22 01:37PM
Dec-08-22 07:00AM
Dec-07-22 09:55AM
Nov-22-22 08:00AM
Nov-16-22 11:26AM
Nov-10-22 07:00AM
Oct-11-22 10:06AM
Oct-06-22 08:00AM
Oct-05-22 06:26AM
Sep-26-22 08:00AM
Sep-10-22 07:00AM
Sep-06-22 08:00AM
Aug-29-22 01:58PM
Aug-11-22 07:00AM
Jun-09-22 12:00PM
May-25-22 03:10PM
May-18-22 12:49PM
May-17-22 08:00AM
May-12-22 07:00AM
May-02-22 04:30PM
Apr-15-22 08:03AM
Apr-06-22 08:00AM
Mar-17-22 07:00AM
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binder GwendolynSee RemarksJan 19 '24Option Exercise1.0111,00011,11031,000Jan 19 06:30 PM
Binder GwendolynSee RemarksJan 19 '24Sale19.5911,000215,43920,000Jan 19 06:30 PM
Binder GwendolynSee RemarksDec 19 '23Option Exercise1.0111,00011,11031,000Dec 19 08:37 PM
Binder GwendolynSee RemarksDec 19 '23Sale21.8911,000240,78920,000Dec 19 08:37 PM
Binder GwendolynSee RemarksNov 20 '23Option Exercise1.0111,00011,11031,000Nov 21 04:30 PM
Binder GwendolynSee RemarksNov 20 '23Sale17.8211,000196,01420,000Nov 21 04:30 PM
Binder GwendolynSee RemarksOct 19 '23Option Exercise1.0111,00011,11031,000Oct 19 07:40 PM
Binder GwendolynSee RemarksOct 19 '23Sale13.3611,000146,92120,000Oct 19 07:40 PM
Binder GwendolynSee RemarksSep 19 '23Option Exercise1.0111,00011,11031,000Sep 20 04:30 PM
Binder GwendolynSee RemarksSep 19 '23Sale17.5711,000193,22020,000Sep 20 04:30 PM
Binder GwendolynSee RemarksAug 21 '23Option Exercise1.0111,00011,11031,000Aug 22 04:30 PM
Binder GwendolynSee RemarksAug 21 '23Sale13.4211,000147,58320,000Aug 22 04:30 PM